Cue Biopharma is trading 5.39% lower at $30.00 in after-hours trading as broader U.S. markets weakened. - On September 23, 2026, the S&P 500 fell 0.73% and the Nasdaq Composite declined 0.67%. - The decline follows a volatile week after positive Phase 2 CUE-221 results in chronic spontaneous urticaria supported advancing toward Phase 2b/3 development. - No new negative company-specific announcement was identified for the after-hours decline.